Evidence map›Paper›PMID 38400071›Full record

ArticleViruses2024

SIV Infection Is Associated with Transient Acute-Phase Steatosis in Hepatocytes In Vivo.

Nina Derby, Sreya Biswas, Sofiya Yusova, Cristina Luevano-Santos, Maria Cristina Pacheco, Kimberly A Meyer, Brooke I Johnson, Miranda Fischer, Katherine A Fancher, Cole Fisher and 6 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Nina DerbyCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA.
Sreya BiswasVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0003-4832-5544
Sofiya YusovaVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Cristina Luevano-SantosCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA.
Maria Cristina PachecoDepartment of Laboratories, Seattle Children's Hospital, Seattle, WA 98105, USA.
Kimberly A MeyerCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA.
Brooke I JohnsonCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA.
Miranda FischerVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Katherine A FancherCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA.ORCID 0000-0002-2719-1797
Cole FisherCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA.
Yohannes M AbrahamCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA.
Conor J McMahonVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Savannah S LutzVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Jeremy V SmedleyVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
Benjamin J BurwitzVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.ORCID 0000-0001-7767-022X
Donald L SodoraCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA.
Infectious Disease Research Institute · USOregon National Primate Research Center · USSeattle Children's Hospital · US

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
Mediators of fatty liver disease during HIV/SIV and cART treatmentR01AI134630 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI SODORA, DONALD L · 2018 to 2022
$4.5M
A Rhesus Macaque Model of HIV and HBV co-infectionR01AI157612 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI BURWITZ, BENJAMIN J · 2021 to 2025
$3.8M
NIAID NIH HHS R01 AI134630NIAID NIH HHS R01 AI157612NIH HHS P51 OD011092NIH HHS P51 OD011107
6 · The paper itself

Abstract

Metabolic-dysfunction-associated fatty liver disease (MAFLD) is a major cause of morbidity and mortality in HIV-infected individuals, even those receiving optimal antiretroviral therapy. Here, we utilized the SIV rhesus macaque model and advanced laparoscopic techniques for longitudinal collection of liver tissue to elucidate the timing of pathologic changes. The livers of both SIV-infected (N = 9) and SIV-naïve uninfected (N = 8) macaques were biopsied and evaluated at four time points (weeks -4, 2, 6, and 16-20 post-infection) and at necropsy (week 32). SIV DNA within the macaques' livers varied by over 4 logs at necropsy, and liver SIV DNA significantly correlated with SIV RNA in the plasma throughout the study. Acute phase liver pathology (2 weeks post-infection) was characterized by evidence for fat accumulation (microvesicular steatosis), a transient elevation in both AST and cholesterol levels within the serum, and increased hepatic expression of the PPARA gene associated with cholesterol metabolism and beta oxidation. By contrast, the chronic phase of the SIV infection (32 weeks post-infection) was associated with sinusoidal dilatation, while steatosis resolved and concentrations of AST and cholesterol remained similar to those in uninfected macaques. These findings suggest differential liver pathologies associated with the acute and chronic phases of infection and the possibility that therapeutic interventions targeting metabolic function may benefit liver health in people newly diagnosed with HIV.

Indexed as

Fatty LiverHIV InfectionsSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnimalsCholesterolDNAHepatocytesHumansMacaca mulattaCholesterolDNAbiopsyhepatocytehistologyHIVlivermetabolismSIVsteatosis

Identifiers

PMID38400071
PMCPMC10892327
OpenAlexW4391837171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.